Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diego F Calvisi

Showing results (1-10 of 234) with videos related to

Pageof 24
Sort By:
Hepatology (Baltimore, Md.)|February 7, 2013
Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: a revolution in hepatocellular carcinoma prevention?Diego F Calvisi
Journal of Hepatology|April 12, 2025
Aberrant ubiquitination causing liver cancer: The ADRM1-ΔEx9- FBXW7 connectionDiego F Calvisi
Hepatology (Baltimore, Md.)|May 29, 2020
Schistosoma mansoni and Hepatocellular Carcinoma: Is It All About c-Jun and Signal Transducer and Activator of Transcription 3?Diego F Calvisi
Hepatology (Baltimore, Md.)|March 5, 2011
Of mice and men: the nonrandom genomic instability in hepatocarcinogenesisDiego F Calvisi
Hepatology (Baltimore, Md.)|May 25, 2011
Dr. Jekyll and Mr. Hyde: a paradoxical oncogenic and tumor suppressive role of signal transducer and activator of transcription 3 in liver cancerDiego F Calvisi
Hepatology (Baltimore, Md.)|January 20, 2016
Accomplices in crime: The diabolical liaison between protein tyrosine phosphatase 1B and ras in hepatocellular carcinomaDiego F Calvisi
Journal of Hepatology|December 3, 2014
Molecularly targeted therapies for human hepatocellular carcinoma: should we start from β-catenin inhibition?Diego F Calvisi
Hepatology (Baltimore, Md.)|November 29, 2014
When good transforming growth factor-β turns bad in hepatocellular carcinoma: Axl takes the stageDiego F Calvisi
Cell Cycle (Georgetown, Tex.)|June 11, 2014
Liver proliferation: the GUCD1/NEDD4-1 connectionDiego F Calvisi
Hepatology (Baltimore, Md.)|September 13, 2016
Programmed death ligand 1 expression in hepatocellular carcinoma: A prognostic marker and therapeutic target for liver cancer?Antonio Solinas, Diego F Calvisi
Pageof 24

Showing results (1-10 of 234) with videos related to

Sort By:
Pageof 24
Hepatology (Baltimore, Md.)|February 7, 2013
Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: a revolution in hepatocellular carcinoma prevention?Diego F Calvisi
Journal of Hepatology|April 12, 2025
Aberrant ubiquitination causing liver cancer: The ADRM1-ΔEx9- FBXW7 connectionDiego F Calvisi
Hepatology (Baltimore, Md.)|May 29, 2020
Schistosoma mansoni and Hepatocellular Carcinoma: Is It All About c-Jun and Signal Transducer and Activator of Transcription 3?Diego F Calvisi
Hepatology (Baltimore, Md.)|March 5, 2011
Of mice and men: the nonrandom genomic instability in hepatocarcinogenesisDiego F Calvisi
Hepatology (Baltimore, Md.)|May 25, 2011
Dr. Jekyll and Mr. Hyde: a paradoxical oncogenic and tumor suppressive role of signal transducer and activator of transcription 3 in liver cancerDiego F Calvisi
Hepatology (Baltimore, Md.)|January 20, 2016
Accomplices in crime: The diabolical liaison between protein tyrosine phosphatase 1B and ras in hepatocellular carcinomaDiego F Calvisi
Journal of Hepatology|December 3, 2014
Molecularly targeted therapies for human hepatocellular carcinoma: should we start from β-catenin inhibition?Diego F Calvisi
Hepatology (Baltimore, Md.)|November 29, 2014
When good transforming growth factor-β turns bad in hepatocellular carcinoma: Axl takes the stageDiego F Calvisi
Cell Cycle (Georgetown, Tex.)|June 11, 2014
Liver proliferation: the GUCD1/NEDD4-1 connectionDiego F Calvisi
Hepatology (Baltimore, Md.)|September 13, 2016
Programmed death ligand 1 expression in hepatocellular carcinoma: A prognostic marker and therapeutic target for liver cancer?Antonio Solinas, Diego F Calvisi
Pageof 24